Background technique [0002] Sermaglutide is a new long-acting glucagon-like peptide-1 (GLP-1) analog developed by Novo Nordisk, which not only has a significant hypoglycemic effect, but also has a significant weight loss effect , the drug is also the second GLP-1 hypoglycemic drug (the other is liraglutide) in Novo Nordisk's diabetes pipeline that has both hypoglycemic and weight loss effects
This dual approach can lead to faster fat loss, better energy utilization, and improved body composition
pharmacies medication shipped directly to your home
Planet Peptide operates as a domestic research peptide vendor, selling lyophilized tirzepatide in 10mg, 30mg, and 60mg vials
Clinical data show that GLP-1 drugs can lower the peak concentration of oral contraceptive hormones by 3050%, which increases breakthrough bleeding and pregnancy risk